SCHEMBL4490544

SCHEMBL4490544

Cc1[nH]c(C)c(-c2c[nH]c(-c3cccc(Cl)c3)cc2=O)c(=O)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.39
EGFR P00533 2/20 0.38
SRC P12931 1/20 0.38
GRM5 P41594 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
PGR P06401 3/20 0.37
NR3C1 P04150 1/20 0.37
NR3C2 P08235 1/20 0.37
AR P10275 1/20 0.37
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
ESR2 Q92731 1/20 0.36
PIM1 P11309 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484311 0.88 BRD4 (0.38) BRD4EGFRSRCGRM5MEN1
SCHEMBL4478743 0.88 SLC2A1 (0.42) BRD4MEN1KMT2AGAAMAPT
SCHEMBL4492022 0.85 MAPT (0.41) MEN1KMT2AMAPTHTTNPC1
SCHEMBL4475367 0.83 ADORA2A (0.39) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL4471113 0.83 XDH (0.40) PIM1
SCHEMBL4481795 0.81 ALDH1A1 (0.43) BRD4MEN1KMT2AMAPTNPC1
SCHEMBL3392240 0.81 PRKAB2 (0.36) BRD4EGFRMEN1KMT2ANPC1
SCHEMBL4473579 0.81 PIM1 (0.41) BRD4MEN1KMT2AGAAHTT
SCHEMBL4483594 0.80 MEN1 (0.31) BRD4MEN1KMT2ANPC1RAB9A
SCHEMBL4482112 0.79 L3MBTL1 (0.39) MEN1KMT2AMAPTNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP BRD4 2655/4885EGFR 4838/4885SRC 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.